Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis

Downstaging of muscle invasive bladder cancer using neoadjuvant gemcitabine and cisplatin or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as single-regimens or switch therapy modalities

(2020) Andrew T. Ruplin et al.   Clinical Genitourinary Cancer

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

(2020) Thomas W. Flaig et al.   Journal of the National Comprehensive Cancer Network

Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence

(2020) Siamak Daneshmand et al.   European Urology Focus

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

(2020) Christian Pfister et al.   EUROPEAN UROLOGY

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

(2020) Jianjun Gao et al.   NATURE MEDICINE

The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer

(2019) Nikhil Waingankar et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies

(2019) Andrea Necchi et al.   EUROPEAN UROLOGY

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

(2019) Thomas Powles et al.   NATURE MEDICINE

Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy

(2018) Homayoun Zargar et al.   JOURNAL OF UROLOGY

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

(2018) Thomas Powles et al.   JOURNAL OF CLINICAL ONCOLOGY

Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer

(2018) Charles C. Peyton et al.   JAMA Oncology

Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

(2017) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature

(2017) Andrea Mari et al.   WORLD JOURNAL OF UROLOGY

Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis

(2016) Ming Yin et al.   ONCOLOGIST

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin

(2015) Elisabeth E. Fransen van de Putte et al.   WORLD JOURNAL OF UROLOGY

Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity

(2014) Elizabeth R. Plimack et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates

(2014) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades

(2013) Pascal Zehnder et al.   BJU INTERNATIONAL

The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses

(2013) W.G. Melsen et al.   CLINICAL MICROBIOLOGY AND INFECTION

Correlation of Pathologic Complete Response with Survival After Neoadjuvant Chemotherapy in Bladder Cancer Treated with Cystectomy: A Meta-analysis

(2013) Fausto Petrelli et al.   EUROPEAN UROLOGY

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

(2012) A. Bamias et al.   ANNALS OF ONCOLOGY

International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial

(2011)   JOURNAL OF CLINICAL ONCOLOGY

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

(2010) Andreas Stang   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE